Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis
Journal of Clinical Investigation · 15.05.2026 · 136 (10)
DOI: 10.1172/jci199285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.05.2026. Verfasst von Qun Lin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Ya…. Hauptthemen laut MEDLINE: RANK Ligand, Bone Neoplasms, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Science and Technology Projects in Guangzhou, Science and Technology Planning Project of Guangdong Province.
Abstract (Originalsprache)
Bone metastasis remains a major cause of morbidity in estrogen receptor–positive breast cancer, with RANKL inhibitor resistance emerging as a critical clinical challenge. Nearly 40% of patients develop progressive skeletal lesions despite denosumab therapy, highlighting an urgent need to identify resistance mechanisms and alternative therapeutic strategies. We identified a RANKL-independent osteoclast activation pathway mediated by the CRKL/circCCDC50/NFATc1 axis. Mechanistically, CRKL promoted EIF4A3-dependent circCCDC50 biogenesis, which was packaged into large oncosomes and transferred to osteoclast precursors. Nuclear circCCDC50 recruited CARM1 to epigenetically activate NFATc1 transcription, establishing a self-reinforcing loop that sustained osteolysis despite RANKL blockade. Pharmacological inhibition of CARM1 (TP-064) effectively suppressed osteoclastogenesis and bone metastasis in denosumab-resistant models. These findings revealed a targetable resistance mechanism and provided a clinically actionable strategy to overcome microenvironment-driven metastasis through dual targeting of tumor and bone niches. Targeting RANKL-independent osteoclastogenesis overcomes Denosumab resistance in models of ER+ breast cancer bone metastasis
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Biochemistry, Zhongshan School of Medicine, Guangzhou, China.
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Science and Technology Projects in Guangzhou
- Science and Technology Planning Project of Guangdong Province
- the Fundamental Research Funds for the Central Universities, Sun Yat-sen University
- High-tech, Major and Characteristic Technology Projects in Guangzhou Are
- National Key R&D Program of China
- Guangdong Provincial Clinical Research Center for Breast Diseases
- Breast Cancer Clinical Research and Treatment Optimization Public Welfare Project
Zitieren
APA
Lin, Q., Luo, J., Duan, Z., Luo, J., Zhang, W., Xia, Y., Zeng, Y., Fang, X., Liang, J., Chen, J., Lin, Q., Quan, Y., Hu, R., Liu, H., Liu, Q., Li, J., & Gong, C. (2026). Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis. Journal of Clinical Investigation, 136(10). https://doi.org/10.1172/jci199285
Vancouver
Lin Q, Luo J, Duan Z, Luo J, Zhang W, Xia Y, et al. Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis. Journal of Clinical Investigation. 2026;136(10). doi:10.1172/jci199285
BibTeX
@article{Lin2026,
author = {Lin, Qun and Luo, Jinpeng and Duan, Zhuxi and Luo, Jieer and Zhang, Wei and Xia, Yuan and Zeng, Yinduo and Fang, Xiaolin and Liang, Jiahui and Chen, Jiayi and Lin, Qianchong and Quan, Yilin and Hu, Ruiyu and Liu, Hongcai and Liu, Qiang and Li, Jun and Gong, Chang},
title = {Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {10},
doi = {10.1172/jci199285}
}
EUVIMED